Surenano Science Ltd · CSE:SURE
Surenano Science — Investor Presentation (October 2026)
22 slides from Surenano Science's investor presentation, Oct 1, 2026
Slide 1: Next Generation GLP Peptide Quickly Progressing Through the FDA Approval Pathway
NEXT GENERATION GLP PEPTIDE QUICKLY PROGRESSING THROUGH THE FDA APPROVAL PATHWAY IN PARTNERSHIP WITH SYRACUSE UNIVERSITY INVESTOR PRESENTATION Q22026 CSE: SURE | OTCQB: SURNF www.surenano.com
Slide 2: Glucapharm advancing Syracuse University's GEP-44 toward FDA approval
GLUCAPHARM INC., 100%-OWNED SUBSIDIARY OF SURENANO SCIENCE LTD. (CSE: SURE, OTCQB:SURNF) IS ADVANCING SYRACUSE UNIVERSITY’S GEP-44, A NEXT-GENERATION GLP FORMULATION (SIMILAR IN FUNCTION TO OZEMPIC®, WEGOVY®, MOUNJARO®, BUT WITH REDUCED RISK OF ADVERSE EVENTS) TOWARDS FDA APPROVAL AND COMMERCIALIZAT
Slide 3: Disclaimer – Forward Looking Information and Statements
DISCLAIMER – Forward Looking Information and Statements This presentation contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than
Slide 4: Metabolic Therapeutics Platform – Next-Generation GLP Science
METABOLIC THERAPEUTICS PLATFORM – Next-Generation GLP Science GLUCAPHARM INC., SUBSIDIARY OF SURENANO SCIENCE LTD. (CSE:SURE, OTCQB: SURNF) IS DEVELOPING A NEXT- GENERATION GLUCAGON-LIKE PEPTIDE (“GLP") GEP-44 IN PARTNERSHIP WITH SYRACUSE UNIVERSITY DESIGNED TO ADDRESS OBESITY AND METABOLIC DISEASE
Slide 5: Rapidly Advancing Through FDA Pathway
RAPIDLY ADVANCING THROUGH FDA PATHWAY – Next-Generation GLP Science MAJOR STEP TOWARD CLINICAL TRIALS ๏ SURENANO SCIENCE LTD. HAS INITIATED FDA-ALIGNED PRECLINICAL STUDIES FOR ITS LEAD DRUG CANDIDATE GEP-44 ๏ PLANNED COLLABORATION WITH LABCORP, A LEADING GLOBAL CRO, FOR PRECLINICAL STUDIES: ENHANCES
Slide 6: GEP-44 Competitive Landscape
GEP-44 RAPIDLY ADVANCING THROUGH FDA PATHWAY – Competitive Landscape Lead Asset / Stage of Targeted Mechanism / Administratio Market Company Patent / IP Differentiation Tolerability Platform Development Sectors Class n Cap Patented: US Application Preclinical IND Obesity, Multi-pathway, Oral / nasal
Slide 7: Targeting High Growth Markets – Next-Generation GLP Science
TARGETING HIGH GROWTH MARKETS – Next-Generation GLP Science The GLP-1 drug market is experiencing massive growth, with sales driven by high demand for obesity and diabetes treatments like Ozempic®, Wegovy®, and Zepbound®, which are reshaping the pharmaceutical landscape OBESITY TO HIT $2 BILLION BY
Slide 8: Growing Opportunity
GROWING OPPORTUNITY 8 SURENANO SCIENCE LTD. CSE: SURE | OTCQB: SURNF www.surenano.com
Slide 9: Executive Summary – Microcap Investment Opportunity
EXECUTIVE SUMMARY – Microcap Investment Opportunity Build A Next-Generation GLP ๏ RARE INVESTMENT OPPORTUNITY IN A MICROCAP, NEXT-GENERATION GLP PEPTIDE THERAPEUTICS COMPANY WITH GLP PORTFOLIO SIMILAR TO BIG PHARMA (LINK): A combination that creates a di erentiated, publicly listed metabolic disease
Slide 10: Lead Asset GEP-44 – Triple-Agonist Design, Single-Molecule Simplicity
LEAD ASSET GEP-44 – Triple-Agonist Design, Single-Molecule Simplicity GEP-44 IS A MONOMERIC PEPTIDE THAT ACTS AS A TRIPLE AGONIST ON GLP-1 AND PEPTIDE YY (PYY) RECEPTORS Y1 AND Y2, COMBINING THE BENEFITS OF GLP-1 AND NPY SIGNALLING PATHWAYS SCIENTIFIC CORE THERAPEUTIC SUPERIOR EFFICACY & TOLERABILIT
Slide 11: Glucapharm's GEP-44 Value Proposition
LEAD ASSET GEP-44 – Triple-Agonist Design, Single-Molecule Simplicity GLUCAPHARM’S GEP-44 VALUE PROPOSITION ๏ PROPRIETARY GEP-44 SOLUTION: A patent-protected, FDA IND STUDY ONGOING RESULTS EXPECTED Q22027 triple-agonist peptide targeting the GLP-1 receptor, Neuropeptide Y1 receptor and Neuropeptide
Slide 12: Research & Publications
RESEARCH & PUBLICATIONS 12 SURENANO SCIENCE LTD. CSE: SURE | OTCQB: SURNF www.surenano.com
Slide 13: Glucapharm's GEP-44 Value Proposition
LEAD ASSET GEP-44 – Triple-Agonist Design, Single-Molecule Simplicity GLUCAPHARM’S GEP-44 VALUE PROPOSITION ๏ DEVELOPING NON-INJECTABLE DELIVERY (ORAL, NASAL OR SUBLINGUAL): Expanding patient adoption and long-term market penetration ๏ COMPETITIVE POSITIONING: Next-generation GLP solution vs rst-and
Slide 14: Lead Asset GEP-44 – Breakthrough Peptides Meet Scalable Delivery
LEAD ASSET GEP-44 – Breakthrough Peptides Meet Scalable Delivery SCIENCE: GEP-44 is part of a series of chimeric peptides designed to target 2 key receptors ๏ Neuropeptide Y-receptor (Y2-R) to reduce food intake (FI), and GLP1-R to improve glucose regulation ๏ In preclinical studies (male and female
Slide 15: FDA Pathway – Accelerated Development Timeline to FDA Approval
FDA PATHWAY – Accelerated Development Timeline to FDA Approval 2025 PRECLINICAL STUDIES Q3-2027- Q2-2032 DEMONSTRATING EFFICACY AND 2025 TOLERABILITY CLINICAL TRIALS PHASE I-III Demonstrates equivalent ef cacy to Ozempic DATA READY FOR IND- Initiate Phase I-III clinical trials to in achieving weight
Slide 16: Market Comparables – Redefining Metabolic Medicine for the Post-Ozempic Era
MARKET COMPARABLES – Rede ning Metabolic Medicine for the Post-Ozempic Era PRECLINICAL EFFICACY IN NEXT-GENERATION GEP-44 HAS THE POTENTIAL TO COMPETE WITH COMPOUNDS DEVELOPED AS OZEMPIC®, MOUNJARO®, WEGOVY® MOUNJARO® - ELI LILLY GEP-44 - SURENANO OZEMPIC® - NOVO NORDISK WEGOVY® - NOVO NORDISK US$22
Slide 17: Value Creation for Shareholders
STRATEGIC PARTNERSHIP VALUE – Vertically Integrated Metabolic Therapeutics Company VALUE CREATION FOR SHAREHOLDERS ๏ RUSH TO FDA APPROVALS WITH IND-STUDIES UNDERWAY: Surenano is among the few companies pursuing this pathway, at a fraction of the cost as big pharmaceutical companies, with anticipated
Slide 18: Management – Led by Experienced Scientific and Capital Markets Executives
MANAGEMENT – Led by Experienced Scienti c and Capital Markets Executives Charles MaLette James Bordian Dr. Robert Doyle Dr. Nihar Pandey Dr. Peter Billing Chief Executive Of cer, Chief Financial Of cer Obesity Expert Inventor and Advisor Chief Scienti c Of cer President and Director and Director and
Slide 19: Cap Table
CORPORATE – Tightly Held with Signi cant Upside Potential CAP TABLE (*08/05/2026) TICKER: CSE:SURE | OTCQB:SURNF HEADQUARTER: VANCOUVER, BC SHARES OUTSTANDING: 42,008,799 OPTIONS: 3,000,000 WARRANTS: 15,600,000 FULLY DILUTED: 60,608,799 MARKET CAP: ~$9.8M OFFICER & DIRECTOR OWNERSHIP: ~26% 52 WEEK H
Slide 20: Contact
CONTACT Nihar Pandey General Chief Scienti c Of cer Corporate Matters e: npandey@surenano.com e: info@surenano.com SURENANO SCIENCE LTD. CSE: SURE | OTCQB: SURNF www.surenano.com fi fi
Slide 21: Appendix
APPENDIX SURENANO SCIENCE LTD. CSE: SURE | OTCQB: SURNF www.surenano.com
Slide 22: Surenano Science Ltd. CSE: SURE | OTCQB: SURNF
22 SURENANO SCIENCE LTD. CSE: SURE | OTCQB: SURNF www.surenano.com
Surenano Science — Investor Presentation (October 2026) on 6ix